玩股撇步(動畫小學堂)  

  • 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
  • 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
  • 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
  • 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
  • 如果EPS衰退,要觀察同業是不是有一樣的狀況
  • 要留意增資減資和公司債對股本及EPS的影響
成長能力-近8季
加權平均股數 QoQ YoYEPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY營收 QoQ YoY毛利率(%) QoQ YoY營業利益率 QoQ YoY稅後淨利率 QoQ YoY營業利益 QoQ YoY稅後淨利 QoQ YoY稅前淨利率(%) QoQ YoY稅後淨利率(%) QoQ YoY兩季平均(YOY)營收成長率(%)兩季平均(YOY)EPS成長率(%)兩季平均(YOY)本業EPS成長率(%)
26Q1 (8)950.00.02.99-24.31968.752.0555.31.492.99-80.221968.7510.744.479.9349.5026.282.6125.4045.644.9227.34-26.031087.02.7352.5115.192.85-24.22000.033.78-19.31014.8527.34-26.031087.0-0.08-31.4466.84
25Q4 (7)950.00.03.95-38.57-2.711.3278.383.9415.1235.3624.4410.28-4.64-11.9139.20-1.61-16.5117.4418.96-5.2736.96-36.955.631.7913.29-16.743.76-38.76-3.0941.86-35.741.4136.96-36.955.63-4.24-3.680.57
25Q3 (6)950.00.06.4331.22524.270.74-77.23-72.3911.17135.6538.0710.78-3.84-12.539.84-28.93-16.5514.66-57.02-42.0858.6237.41621.921.58-58.64-49.366.1431.48520.265.1435.2416.1658.6237.41621.925.451596.86-8.17
25Q2 (5)950.00.04.903162.574.383.2560.89301.234.743062.5-32.7711.2114.74-3.6156.0616.2131.1334.1140.89148.842.661640.0777.823.8261.18140.254.673213.3374.2548.181490.160.1242.661640.0777.82--0.00
25Q1 (4)950.00.0-0.16-103.940.02.0259.060.0-0.16-101.320.09.77-16.280.048.242.750.024.2131.50.0-2.77-107.920.02.3710.230.0-0.15-103.870.03.03-92.660.0-2.77-107.920.0--0.00
24Q4 (3)950.00.04.06294.170.01.27-52.610.012.1550.190.011.67-5.280.046.95-1.650.018.41-27.260.034.99330.910.02.15-31.090.03.88291.920.041.28227.10.034.99330.910.0--0.00
24Q3 (2)950.00.01.03-63.350.02.68230.860.08.0914.750.012.325.930.047.7411.670.025.3184.610.08.12-66.150.03.1296.230.00.99-63.060.012.62-58.060.08.12-66.150.0--0.00
24Q2 (1)950.00.02.810.00.00.810.00.07.050.00.011.630.00.042.750.00.013.710.00.023.990.00.01.590.00.02.680.00.030.090.00.023.990.00.0--0.00
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2026/43.68-17.09-6.1814.435.3510.74N/A-
2026/34.4469.4448.710.749.9910.741.19-
2026/22.62-28.8-15.636.3-7.0510.381.23-
2026/13.68-9.690.23.680.211.111.15-
2025/124.0821.756.2742.04-9.4110.281.23-
2025/113.3517.16-13.8737.96-10.829.931.28-
2025/102.86-23.19-27.6234.62-10.519.361.35-
2025/93.7233.65-15.7731.76-8.5710.781.21-
2025/82.78-34.89-25.9528.04-7.5210.591.23-
2025/74.2821.173.2125.25-4.9111.561.13-
2025/63.53-6.09-9.8120.98-6.4111.211.24-
2025/53.76-4.26-1.0917.45-5.710.671.3-
2025/43.9231.40.0313.69-6.8910.021.39-
2025/32.99-3.87-19.759.77-9.419.771.3-
2025/23.11-15.438.636.78-3.9610.621.2-
2025/13.67-4.21-12.543.67-12.5411.41.11-
2024/123.84-1.3214.446.41-3.4511.671.04-
2024/113.89-1.549.4442.57-4.7912.250.99-
2024/103.95-10.611.7638.69-6.0212.131.0-
2024/94.4217.4920.8834.74-6.8312.320.98-
2024/83.76-9.2425.9230.32-9.8411.811.02-
2024/74.145.8823.0926.56-13.3211.851.01-
2024/63.912.98-0.2822.42-17.8211.631.01-
2024/53.8-3.17-18.4718.51-20.7611.441.03-
2024/43.925.4117.5414.71-21.3310.511.12-
2024/33.7230.13-9.710.78-29.7810.78N/A-
2024/22.86-31.92-34.997.06-37.1510.41N/A-
2024/14.225.29-38.544.2-38.5411.11N/A-
2023/123.35-5.6-30.6148.07-50.0610.78N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/113.55-8.45-14.0744.72-51.0911.09N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/103.886.17-57.5941.16-52.8410.52N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/93.6522.38-42.5337.28-52.2910.01N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/82.99-11.28-45.9133.63-53.1510.27N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/73.37-14.21-72.130.64-53.7511.95N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/63.92-15.79-66.7727.28-49.6711.92N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/54.6639.59-61.3923.36-44.9112.12N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/43.34-19.02-73.0818.7-38.3511.86N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售減少
2023/34.12-6.31-27.2415.36-14.3315.36N/A-
2023/24.4-35.64-8.6911.24-8.3716.07N/A-
2023/16.8441.47-8.166.84-8.1615.8N/A-
2022/124.8316.898.6396.2748.2518.12N/A-
2022/114.13-54.82-20.8291.4451.1719.64N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售增加
2022/109.1543.9127.287.357.9721.03N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售增加
2022/96.3615.18-4.7678.1552.5323.95N/A本年係因新冠肺炎抗原快篩檢驗試劑銷售增加
2022/85.52-54.24-24.5771.7961.1129.39N/A因新冠肺炎抗原快篩檢驗試劑銷售減少
2022/712.072.1972.4566.2777.9635.94N/A因新冠肺炎抗原快篩檢驗試劑銷售增加
2022/611.81-2.1630.8354.2179.2336.28N/A因新冠肺炎抗原快篩檢驗試劑銷售增加
2022/512.07-2.68171.0642.499.8130.14N/A因新冠肺炎抗原快篩檢驗試劑銷售增加
2022/412.4118.89275.6930.3380.8922.89N/A因新冠肺炎抗原快篩檢驗試劑銷售增加
2022/35.6717.5731.0417.9333.1417.93N/A-
2022/24.82-35.2725.3812.2634.1316.71N/A-
2022/17.4467.3540.487.4440.4817.11N/A-
2021/124.45-14.79-21.2664.9310.1513.7N/A-
2021/115.2229.6235.7360.4813.4815.93N/A-
2021/104.03-39.68-9.5755.2611.7518.02N/A-
2021/96.68-8.7622.7551.2413.8620.99N/A-
2021/87.324.6169.144.5612.6423.34N/A因新冠肺炎抗原快篩檢驗試劑銷售增加
2021/77.0-22.4734.3237.245.720.47N/A-
2021/69.02102.6893.2230.240.740.0N/A因新冠肺炎抗原快篩檢驗試劑銷售增加
2021/54.4534.88-30.0321.22-16.290.0N/A-
成長能力-近5年
加權平均股數 YoYEPS YoY本業EPS YoY營收 YoY毛利率(%) YoY營業利益率 YoY稅後淨利率 YoY營業利益 YoY稅前淨利 YoY稅後淨利 YoY
2025 (5)950.015.0224.757.3338.0442.04-9.4245.963.8422.7430.0934.8034.269.5617.8817.0216.114.4224.42
2024 (4)950.012.0413.375.31-23.2746.41-3.4544.262.6417.48-13.2125.9218.368.11-16.2214.6610.3911.5913.96
2023 (3)951.0610.62-69.746.92-79.1648.07-50.0743.12-26.4820.14-53.1721.90-39.229.68-76.6213.28-69.610.17-69.94
2022 (2)941.0835.1070.3133.21102.596.2748.2758.6518.6843.0133.2836.0314.4541.4197.6643.6973.9333.8371.29
2021 (1)934.4920.6125.9816.402.5664.939.9849.42032.27031.48020.955.725.1226.6119.7529.85

財務分析相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。